{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:51:49Z","timestamp":1771663909958,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":283,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Surgery Case Reports"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/j.ijscr.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T13:49:29Z","timestamp":1540388969000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status"],"prefix":"10.1097","volume":"53","author":[{"given":"Sunny","family":"Dhadlie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasika","family":"Hendahewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.ijscr.2018.10.016_bib0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijsu.2016.08.014","article-title":"The SCARE statement: consensus-based surgical case report guidelines","volume":"34","author":"Agha","year":"2016","journal-title":"Int. J. Surg."},{"issue":"227","key":"10.1016\/j.ijscr.2018.10.016_bib0010","article-title":"Tumor heterogeniety in breast Cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0015","series-title":"AJCC Cancer Staging Manual \u2013 Breast","author":"Hortobagyi","year":"2017"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0020","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0025","series-title":"WHO Classification of Tumours of the Breast","year":"2012"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/00000478-200306000-00016","article-title":"Special types of invasive breast cancer, with clinical implications","volume":"27","author":"Page","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0035","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdp245","article-title":"Breast carcinoma \u2013 rare types: review of the literature","volume":"20","author":"Yerushalmi","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological types of breast cancer: how special are they?","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.breast.2011.12.011","article-title":"The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics","volume":"21","author":"Nagao","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston","year":"1991","journal-title":"Histopathology"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0055","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/0008-5472.CAN-03-2430","article-title":"A molecular signature of the Nottingham prognostic index in breast cancer","volume":"64","author":"Yu","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0060","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0065","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","article-title":"Molecular heterogeneity in breast cancer: state of the science and implications for patient care","volume":"64","author":"Ellsworth","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0080","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/bjc.2014.341","article-title":"The AURORA initiative for metastatic breast cancer","volume":"111","author":"Zardavas","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0085","first-page":"1597","article-title":"Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer","volume":"57","author":"Kuukasjarvi","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nature08489","article-title":"Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution","volume":"461","author":"Shah","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.1691","article-title":"Molecular evolution of breast cancer","volume":"205","author":"Simpson","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10549-011-1601-4","article-title":"PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression","volume":"129","author":"Kalinsky","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0105","first-page":"36","article-title":"Discordance of receptor status in breast cancer throughout tumor progression and the associated prognostic implications: a case report and review of the literature","year":"2016","journal-title":"Spranklin L, Nair S. Cancer Treat. Commun."},{"issue":"2","key":"10.1016\/j.ijscr.2018.10.016_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2014.12.001","article-title":"Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers","volume":"24","author":"Baretta","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.ijscr.2018.10.016_bib0115","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdp263","article-title":"Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer","volume":"20","author":"Liedtke","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/oxfordjournals.annonc.a058330","article-title":"Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance","volume":"3","author":"Spataro","year":"1992","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijscr.2018.10.016_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-004-2756-z","article-title":"Impact of metastatic estrogen receptor and progesterone receptor status on survival","volume":"90","author":"Lower","year":"2005","journal-title":"Breast Cancer Res. Treat."}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261218304395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261218304395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:39:22Z","timestamp":1768387162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210261218304395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"alternative-id":["S2210261218304395"],"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2018.10.016","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status","name":"articletitle","label":"Article Title"},{"value":"International Journal of Surgery Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijscr.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}]}}